Show notes
Cardiovascular professionals are coming together for ACC.23 in New Orleans, March 4-6, to learn the latest practice-changing breakthrough research and trials results from around the world. In this View episode, guest host Deepak Bhatt MD, MPH, FACC, offers a preview of some of the hottest trials at ACC.23.
Kicking us off on Day 1, Saturday, March 4, we will hear the positive outcomes from the CLEAR OUTCOMES trial and the favorable data for structural heart disease coming out of the TRILUMINATE trial.
Day 2, Sunday, March 5, can’t be missed! Among the many presentations: UK MINI MITRAL weighs the minimally invasive approach versus conventional sternotomy for mitral valve repair surgery and the RENOVATE COMPLEX PCI trial that examines intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention – a subject of particular interest to interventionalists. And that’s just the beginning: the 5-year final results from the COAPT trial are in; the 3-year outcomes from the EVOLUT low risk trial sound positive and continue to be in favor of TAVR; the BIOVASC trial data will be released, and it’s likely the findings will continue to be in favor of complete revascularization strategies in patients presenting with acute coronary syndromes and multivessel coronary disease.
On Monday, the last day of the conference, Dr. Valentin Fuster will present the FREEDOM COVID ANTICOAG trial, discussing anticoagulation strategies in non-critically ill hospitalized COVID patients. Next up, the STELLAR trial, a study of sotatercept in combination with background therapy for the treatment of pulmonary arterial hypertension, will be presented. And finally, the findings of the collaborative analysis of participants in the three major trials are also scheduled: the PROMINENT, REDUCE-IT, STRENGTH trials.
Be sure to check back on Eagle's Eye View throughout the meeting for further updates.
Subscribe to Eagle’s Eye View
Our TOPPODCAST Picks 
Stay Connected
